Developer docs
API playgroundTry for free, no card

Search company profiles

Nxera Pharma

Full company profile

uuid000418w

Namestring
Nxera Pharma
Legal namestring
Nxera Pharma Co., Ltd.
Websiteurl
nxera.life
Company typeenum
Public
Founded yearint
1990
Descriptiontext

Nxera Pharma Co., Ltd. (formerly Sosei Group, rebranded April 2024) is a Japan-headquartered, technology-driven biopharmaceutical company that designs and develops therapeutics targeting G protein-coupled receptors (GPCRs). The company operates from a Tokyo headquarters and a UK R&D hub in Cambridge, with additional offices in London, Basel and Seoul, and trades publicly on the Tokyo Stock Exchange (TSE: 4565) and OTCMKTS (SOLTF). Its core technology is the NxWave™ GPCR structure-based drug discovery platform, which integrates NxStaR™ (proprietary GPCR structure determination via X-ray crystallography and cryo-EM, supported by patented miniG protein technology), NxHit™ (virtual, GPCR-focused library and DNA-encoded library screening), and NxDesign™ (computational-chemistry and machine-learning-enabled structure-based drug design). Nxera has solved more than 500 GPCR structures and uses the platform both to advance a 30+ program internal pipeline (spanning obesity, metabolic, endocrine, neurology and immuno-oncology indications) and to power multi-year discovery collaborations with AbbVie, Eli Lilly, Neurocrine Biosciences, Centessa, Cancer Research UK and the NewCo GPCR spin-out.

The company's revenue model is a hybrid of (i) direct product commercialization in Japan and select APAC markets (PIVLAZ/clazosentan for cerebral vasospasm prevention, generating JPY 13,511M in FY2025 with 25,470 patients treated, and QUVIVIQ/daridorexant for insomnia, which grew 223.9% to JPY 4,327M); (ii) licensing and milestone payments from out-licensed and partnered programs (FY2025 milestone receipts of US$35M; up to US$1.2B remaining from AbbVie, US$694M from Eli Lilly, and US$205M-plus from the Santhera Agamree deal); and (iii) tiered royalties on global sales of partnered assets. Distribution in Japan is executed directly and via channel partnerships (Shionogi for QUVIVIQ), while ex-APAC rights are typically out-licensed to major pharma for global commercialization. FY2025 total revenue was JPY 29.6 billion (~US$197.9M), and the company is targeting full-year profitability in FY2026 supported by a November 2025 strategic restructuring (15% workforce reduction, ~JPY 1B in annual savings) and a JPY 3.5B planned reduction in R&D spend.

Short descriptiontext

Nxera Pharma is a Japan-headquartered biopharmaceutical company that uses its proprietary NxWave™ GPCR structure-based drug discovery platform to develop therapeutics, commercializing PIVLAZ and QUVIVIQ in Japan/APAC and licensing assets globally to AbbVie, Eli Lilly, and other major pharma partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
GPCR drug discovery, structure-based drug design, biopharmaceutical development, neurological disease therapeutics, metabolic disorder treatments
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals (GPCR-targeted drug discovery and development)
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Product Sales
TypeOne Time License
Description

Commercial revenues from marketed products including PIVLAZ® (clazosentan) for cerebral vasospasm prevention and QUVIVIQ™ (daridorexant) for insomnia. PIVLAZ grew 6.8% to JPY 13,511 million; QUVIVIQ surged 223.9% to JPY 4,327 million in FY2025

biospace.com
2Milestone Payments
TypeLicensing Royalties
Description

One-time payments received upon achievement of specific R&D milestones under collaboration agreements. Received US$10 million from AbbVie (4th milestone), US$22.5 million from Neurocrine Biosciences Phase 2 trial, US$3 million from Centessa for ORX489 milestone

globenewswire.com
3Development and Commercial Milestones
TypeLicensing Royalties
Description

Potential future milestone payments under partnerships: up to US$1.2 billion from AbbVie (neurological diseases), up to US$694 million from Eli Lilly (metabolic diseases), up to US$275 million from GPCR spin-out NewCo

globenewswire.com
4Tiered Royalties
TypeLicensing Royalties
Description

Ongoing royalties on global sales from partnered programs including AbbVie neurological collaborations, Eli Lilly metabolic collaborations, and Centessa OX2R agonist pipeline

thepharmaletter.com
5Licensing Revenue
TypeLicensing Royalties
Description

Upfront payments and ongoing licensing fees from out-licensing arrangements such as Santhera agreement (US$40 million upfront for Agamree/vamorolone in Japan, South Korea, Australia, New Zealand)

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1PIVLAZ and QUVIVIQ products commercialized in Japan with Shionogi distribution partnership
ModelOtherBilling cadenceOther
Notes

Product pricing subject to National Health Insurance pricing in Japan; Shionogi partnership for distribution in Japan

biospace.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1NxWave
Description

Proprietary GPCR structure-based drug discovery platform

nxera.life
+5 more records
Core offering1 text field

Nxera Pharma is a technology-driven biopharmaceutical company that discovers, develops, and commercializes medicines targeting G protein-coupled receptors (GPCRs). Its proprietary NxWave™ platform supports structure-based drug design, and the company markets two products in Japan — PIVLAZ (clazosentan) for cerebral vasospasm prevention and QUVIVIQ (daridorexant) for insomnia — while also generating revenue through licensing deals, milestone payments, and royalties from global pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 500+ GPCR structures solved and counting
+7 more records
Product overview1 text field

Nxera Pharma is a next-generation, technology-driven biopharma company with a proprietary drug discovery platform for G protein-coupled receptors (GPCRs). The company's core technology is the NxWave™ platform, which encompasses NxStaR™ (structural biology), NxHit™ (compound screening), and NxDesign™ (structure-based drug design). The commercial portfolio includes two marketed products: PIVLAZ™ (clazosentan) for cerebral vasospasm prevention and QUVIVIQ™ (daridorexant) for insomnia. The pipeline spans multiple therapeutic areas including neurology (schizophrenia programs, muscarinic agonists), immunology (EP4 programs, GPR35 agonist), metabolic disorders (GLP-1, GIP, amylin programs), and oncology (EP4 antagonist partnered with Cancer Research UK). Nxera also licenses in products such as vamorolone for Duchenne muscular dystrophy. The company operates across Japan, UK, Switzerland, and South Korea with over 500 GPCR structures solved.

Product and service4 records
1PIVLAZ (clazosentan)
CategoryMarketed pharmaceutical product
Description

Marketed endothelin receptor antagonist indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH). Commercialized in Japan with FY2025 revenue of JPY 13,511 million (up 6.8% year-on-year); over 25,470 patients have been treated in Japan.

2QUVIVIQ (daridorexant)
CategoryMarketed pharmaceutical product
Description

Dual orexin receptor antagonist for the treatment of insomnia disorder. Marketed in Japan via the Shionogi distribution partnership; FY2025 revenue surged 223.9% year-on-year to JPY 4,327 million. A Phase 3 trial in South Korea met all primary and secondary endpoints.

3Agamree (vamorolone)
CategoryLicensed / in-licensed pharmaceutical product
Description

In-licensed novel corticosteroid alternative for Duchenne muscular dystrophy, licensed from Santhera Pharmaceuticals for development, manufacturing, and commercialization in Japan, South Korea, Australia, and New Zealand under a deal valued at up to US$205 million in upfront and milestone payments plus double-digit tiered royalties.

4NxWave™ Platform (Drug Discovery Service)
CategoryDrug discovery platform / collaboration service
Description

Proprietary GPCR-focused structure-based drug discovery service offered to pharmaceutical partners through multi-target collaborations, option-to-license agreements, and out-licensing arrangements. The platform underpins partnerships with AbbVie (neurological diseases, up to US$1.2B in potential milestones), Eli Lilly (metabolic diseases, up to US$694M in potential milestones), Neurocrine Biosciences, Centessa Pharmaceuticals, and a GPCR spin-out NewCo (up to US$275M in potential milestones).

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-06-10
Description

Nxera joined OpenFold, a non-profit AI research consortium developing open-source AI software tools for biology and drug discovery. Membership enables leveraging state-of-the-art open-source structural prediction models to create synergies with proprietary NxWave™ platform to accelerate GPCR target-focused drug discovery. Consortium includes Bristol Myers Squibb, Novo Nordisk, Bayer, Roche as pharmaceutical members, and Amazon Web Services, Microsoft, NVIDIA as supporting technology members.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-05-11
Description

Nxera closed licensing agreement and Series A financing with newly formed company for GPCR-targeted pre-clinical program discovered using NxWave technology platform. Granted exclusive worldwide license while retaining Japan and certain Asia-Pacific territories. Eligible to receive up to US$275 million in development and commercial milestones plus tiered royalties. Nxera holds significant minority equity stake; Chief Scientific Officer joined NewCo's Board of Directors.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-12
Description

Neurocrine Biosciences dosing first patient in Phase 2 trial of NBI-1117570 (dual muscarinic M1/M4 receptor agonist) for adults with schizophrenia. Triggered US$22.5 million milestone payment to Nxera, recognized as Q1 FY2026 revenue. Phase 2 double-blind, placebo-controlled trial enrolling approximately 120 patients with primary endpoint of change from baseline in PANSS total score.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-31
Description

Centessa Pharmaceuticals entered into definitive agreement to be acquired by Eli Lilly. Nxera jointly discovered OX2R agonist pipeline (cleminorexton/ORX750, ORX142, ORX489) using Nxera's NxStaR technology. Nxera retains entitlement to milestone payments and royalties from all OX2R agonists unaffected by acquisition. Nxera holds equity interest in Centessa. Early milestone of US$3 million achieved for ORX489 in March 2026.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-08
Description

Santhera granted Nxera exclusive licensing agreement for development, manufacturing, and commercialization of Agamree (vamorolone) for Duchenne muscular dystrophy in Japan, South Korea, Australia, and New Zealand. Nxera paying US$40 million upfront (US$30 million cash + US$10 million equity investment) with additional potential milestones up to US$165 million plus double-digit tiered royalties on net sales.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-31
Description

Partnership with Shionogi for product distribution in Japan supporting QUVIVIQ (daridorexant) demand in Japan and across Asia-Pacific region. Manufacturing approval received for second API manufacturing site in Asia to reduce costs and improve profitability from 2027.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-21
Description

Partnership for cancer immunotherapy drug HTL0039732 (EP4 antagonist). Phase 1 trial successfully completed demonstrating safety and tolerability with early efficacy. Phase 2 expansion trial underway in Japan and UK sponsored by Cancer Research UK. Partial responses observed in patients with resistant tumors including metastatic renal cell and colorectal cancers.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Multi-target discovery collaboration targeting neurological diseases. Nxera achieved fourth R&D milestone in June 2026 (US$10 million payment), bringing total received to US$40 million since 2022. Nxera remains eligible for up to US$1.2 billion in additional potential option, development and commercial milestones, plus tiered royalties on global sales. Collaboration uses NxWave™ GPCR structure-based drug discovery platform.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Multi-target collaboration targeting diabetes and metabolic diseases. Second development milestone achieved in April 2026, validating Nxera's NxWave™ GPCR platform by identifying small molecule binders and solving receptor structures. Nxera eligible for up to US$694 million in development and commercial milestones plus tiered royalties on global sales. Lilly assumes responsibility for further development and commercialization.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-listed (SDGR) computational/structure-based drug design platform company with a software-plus-collaborative-discovery model. Highly comparable to Nxera's NxWave™ platform in combining physics-based modeling, ML, and a wet-lab pipeline to generate partnered and proprietary therapeutic candidates.

TypeBroad incumbent
Description

Diversified Japanese pharma group with significant CNS/psychiatry and specialty disease franchises including schizophrenia. Comparable in CNS therapeutic-area focus and in the Japanese listed-pharma landscape, providing a reference for partner-of-choice economics in Japanese CNS.

TypeBroad incumbent
Description

Swiss-listed specialty CNS biopharma whose operations were integrated into Nxera in 2026. Closely comparable in therapeutic focus (neurology, sleep, rare diseases) and brings daridorexant/QUVIVIQ history to the Nxera platform; a useful reference for what Nxera's CNS specialty pharma footprint could scale to.

TypeRegional player
Description

Major Japanese pharmaceutical company and Nxera's distribution partner for QUVIVIQ in Japan/APAC. A relevant Japanese peer given overlapping CNS/anti-infective portfolio and Shionogi's role in commercializing Nxera's CNS products in the home market.

TypeEmerging player
Description

UK-based GPCR-focused drug discovery company using native mass spectrometry and structural biology. Direct comparability in GPCR-focused discovery and the named defendant in Nxera's miniG patent infringement action, making it a particularly informative peer on technology overlap and IP risk.

TypeBroad incumbent
Description

CNS-focused biopharma (now part of BMS) that developed muscarinic M1/M4 agonism for schizophrenia. Direct comparability to Nxera's muscarinic program (NBI-1117570 with Neurocrine) and schizophrenia franchise including GPR52.

TypeEmerging player
Description

AI-centric drug discovery company (EXAI) that has signed multi-target discovery deals with major pharma. Similar to Nxera in the partnered-collaborative revenue model and tech-driven pipeline generation, though Exscientia uses AI/automation rather than GPCR structural biology.

8Eisai Co., Ltd.
TypeBroad incumbent
Description

Large Japanese pharmaceutical company with significant CNS, neurology, and rare-disease franchises. Comparable in scale and therapeutic-area overlap to Nxera's Japanese CNS commercial footprint and serves as a reference for what a profitable Japan-listed CNS biopharma looks like at scale.

TypeEmerging player
Description

AI-driven drug discovery platform (RXRX) combining high-throughput biology with ML. Comparable to Nxera in the technology-powered biopharma category, though Recursion's data-generation and target-discovery emphasis is distinct from Nxera's GPCR-structure specialization.

TypeBroad incumbent
Description

CNS-focused biopharma (now part of AbbVie) with development programs across schizophrenia, Parkinson's, and epilepsy. Comparable in CNS therapeutic focus and a relevant comparable for the value a partnered CNS asset can capture under AbbVie's umbrella — Nxera's own AbbVie partnership uses the same major pharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nxera Pharma

Biopharmaceuticals (GPCR-targeted drug discovery and development)nxera.life

Nxera Pharma is a Japan-headquartered biopharmaceutical company that uses its proprietary NxWave™ GPCR structure-based drug discovery platform to develop therapeutics, commercializing PIVLAZ and QUVIVIQ in Japan/APAC and licensing assets globally to AbbVie, Eli Lilly, and other major pharma partners.

What Nxera Pharma does

Nxera Pharma Co., Ltd. (formerly Sosei Group, rebranded April 2024) is a Japan-headquartered, technology-driven biopharmaceutical company that designs and develops therapeutics targeting G protein-coupled receptors (GPCRs). The company operates from a Tokyo headquarters and a UK R&D hub in Cambridge, with additional offices in London, Basel and Seoul, and trades publicly on the Tokyo Stock Exchange (TSE: 4565) and OTCMKTS (SOLTF). Its core technology is the NxWave™ GPCR structure-based drug discovery platform, which integrates NxStaR™ (proprietary GPCR structure determination via X-ray crystallography and cryo-EM, supported by patented miniG protein technology), NxHit™ (virtual, GPCR-focused library and DNA-encoded library screening), and NxDesign™ (computational-chemistry and machine-learning-enabled structure-based drug design). Nxera has solved more than 500 GPCR structures and uses the platform both to advance a 30+ program internal pipeline (spanning obesity, metabolic, endocrine, neurology and immuno-oncology indications) and to power multi-year discovery collaborations with AbbVie, Eli Lilly, Neurocrine Biosciences, Centessa, Cancer Research UK and the NewCo GPCR spin-out.

The company's revenue model is a hybrid of (i) direct product commercialization in Japan and select APAC markets (PIVLAZ/clazosentan for cerebral vasospasm prevention, generating JPY 13,511M in FY2025 with 25,470 patients treated, and QUVIVIQ/daridorexant for insomnia, which grew 223.9% to JPY 4,327M); (ii) licensing and milestone payments from out-licensed and partnered programs (FY2025 milestone receipts of US$35M; up to US$1.2B remaining from AbbVie, US$694M from Eli Lilly, and US$205M-plus from the Santhera Agamree deal); and (iii) tiered royalties on global sales of partnered assets. Distribution in Japan is executed directly and via channel partnerships (Shionogi for QUVIVIQ), while ex-APAC rights are typically out-licensed to major pharma for global commercialization. FY2025 total revenue was JPY 29.6 billion (~US$197.9M), and the company is targeting full-year profitability in FY2026 supported by a November 2025 strategic restructuring (15% workforce reduction, ~JPY 1B in annual savings) and a JPY 3.5B planned reduction in R&D spend.

Nxera Pharma firmographics

Firmographics
Name
Nxera Pharma
Legal name
Nxera Pharma Co., Ltd.
Website
https://nxera.life
Company type
Public
Founded year
1990
Operating status
Operating
Headcount range
251–500 employees
Short description
Nxera Pharma is a Japan-headquartered biopharmaceutical company that uses its proprietary NxWave™ GPCR structure-based drug discovery platform to develop therapeutics, commercializing PIVLAZ and QUVIVIQ in Japan/APAC and licensing assets globally to AbbVie, Eli Lilly, and other major pharma partners.
Ownership category
akta.pro rank

Nxera Pharma industry classification

Industry
Product category
Biopharmaceuticals (GPCR-targeted drug discovery and development)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • GPCR drug discovery
  • Structure-based drug design
  • Biopharmaceutical development
  • Neurological disease therapeutics
  • Metabolic disorder treatments

Where Nxera Pharma is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices5 records

Markets served

Nxera Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Product Sales: Commercial revenues from marketed products including PIVLAZ® (clazosentan) for cerebral vasospasm prevention and QUVIVIQ™ (daridorexant) for insomnia. PIVLAZ grew 6.8% to JPY 13,511 million; QUVIVIQ surged 223.9% to JPY 4,327 million in FY2025
  2. Milestone Payments: One-time payments received upon achievement of specific R&D milestones under collaboration agreements. Received US$10 million from AbbVie (4th milestone), US$22.5 million from Neurocrine Biosciences Phase 2 trial, US$3 million from Centessa for ORX489 milestone
  3. Development and Commercial Milestones: Potential future milestone payments under partnerships: up to US$1.2 billion from AbbVie (neurological diseases), up to US$694 million from Eli Lilly (metabolic diseases), up to US$275 million from GPCR spin-out NewCo
  4. Tiered Royalties: Ongoing royalties on global sales from partnered programs including AbbVie neurological collaborations, Eli Lilly metabolic collaborations, and Centessa OX2R agonist pipeline
  5. Licensing Revenue: Upfront payments and ongoing licensing fees from out-licensing arrangements such as Santhera agreement (US$40 million upfront for Agamree/vamorolone in Japan, South Korea, Australia, New Zealand)

Pricing tiers

ModelBillingPrice
OtherOtherPIVLAZ and QUVIVIQ products commercialized in Japan with Shionogi distribution partnership

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Nxera Pharma product offering

Product offering

Core offering

Nxera Pharma is a technology-driven biopharmaceutical company that discovers, develops, and commercializes medicines targeting G protein-coupled receptors (GPCRs). Its proprietary NxWave™ platform supports structure-based drug design, and the company markets two products in Japan — PIVLAZ (clazosentan) for cerebral vasospasm prevention and QUVIVIQ (daridorexant) for insomnia — while also generating revenue through licensing deals, milestone payments, and royalties from global pharmaceutical partners.

Product overview

Nxera Pharma is a next-generation, technology-driven biopharma company with a proprietary drug discovery platform for G protein-coupled receptors (GPCRs). The company's core technology is the NxWave™ platform, which encompasses NxStaR™ (structural biology), NxHit™ (compound screening), and NxDesign™ (structure-based drug design). The commercial portfolio includes two marketed products: PIVLAZ™ (clazosentan) for cerebral vasospasm prevention and QUVIVIQ™ (daridorexant) for insomnia. The pipeline spans multiple therapeutic areas including neurology (schizophrenia programs, muscarinic agonists), immunology (EP4 programs, GPR35 agonist), metabolic disorders (GLP-1, GIP, amylin programs), and oncology (EP4 antagonist partnered with Cancer Research UK). Nxera also licenses in products such as vamorolone for Duchenne muscular dystrophy. The company operates across Japan, UK, Switzerland, and South Korea with over 500 GPCR structures solved.

Differentiator

Problem solved

Functional benefit

Brands

  • NxWave: Proprietary GPCR structure-based drug discovery platform
  • NxStaR
  • NxHit
  • NxDesign
  • PIVLAZ
  • QUVIVIQ

Products and services

  • PIVLAZ (clazosentan) Marketed endothelin receptor antagonist indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH). Commercialized in Japan with FY2025 revenue of JPY 13,511 million (up 6.8% year-on-year); over 25,470 patients have been treated in Japan.
  • QUVIVIQ (daridorexant) Dual orexin receptor antagonist for the treatment of insomnia disorder. Marketed in Japan via the Shionogi distribution partnership; FY2025 revenue surged 223.9% year-on-year to JPY 4,327 million. A Phase 3 trial in South Korea met all primary and secondary endpoints.
  • Agamree (vamorolone) In-licensed novel corticosteroid alternative for Duchenne muscular dystrophy, licensed from Santhera Pharmaceuticals for development, manufacturing, and commercialization in Japan, South Korea, Australia, and New Zealand under a deal valued at up to US$205 million in upfront and milestone payments plus double-digit tiered royalties.
  • NxWave™ Platform (Drug Discovery Service) Proprietary GPCR-focused structure-based drug discovery service offered to pharmaceutical partners through multi-target collaborations, option-to-license agreements, and out-licensing arrangements. The platform underpins partnerships with AbbVie (neurological diseases, up to US$1.2B in potential milestones), Eli Lilly (metabolic diseases, up to US$694M in potential milestones), Neurocrine Biosciences, Centessa Pharmaceuticals, and a GPCR spin-out NewCo (up to US$275M in potential milestones).

Quantifiable outcome

  • 500+ GPCR structures solved and counting
  • +7 more outcomes

Companies that use Nxera Pharma

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Nxera Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Nxera Pharma partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered strategic, core and flagship.

  • OpenFold AI Research ConsortiumstrategicTechnology or Integration · 10 June 2026Nxera joined OpenFold, a non-profit AI research consortium developing open-source AI software tools for biology and drug discovery. Membership enables leveraging state-of-the-art open-source structural prediction models to create synergies with proprietary NxWave™ platform to accelerate GPCR target-focused drug discovery. Consortium includes Bristol Myers Squibb, Novo Nordisk, Bayer, Roche as pharmaceutical members, and Amazon Web Services, Microsoft, NVIDIA as supporting technology members.
  • NewCo (GPCR Spin-out)strategicStrategic or Co-development Partner · 11 May 2026Nxera closed licensing agreement and Series A financing with newly formed company for GPCR-targeted pre-clinical program discovered using NxWave technology platform. Granted exclusive worldwide license while retaining Japan and certain Asia-Pacific territories. Eligible to receive up to US$275 million in development and commercial milestones plus tiered royalties. Nxera holds significant minority equity stake; Chief Scientific Officer joined NewCo's Board of Directors.
  • Neurocrine BiosciencescoreStrategic or Co-development Partner · 12 April 2026Neurocrine Biosciences dosing first patient in Phase 2 trial of NBI-1117570 (dual muscarinic M1/M4 receptor agonist) for adults with schizophrenia. Triggered US$22.5 million milestone payment to Nxera, recognized as Q1 FY2026 revenue. Phase 2 double-blind, placebo-controlled trial enrolling approximately 120 patients with primary endpoint of change from baseline in PANSS total score.
  • Centessa PharmaceuticalscoreStrategic or Co-development Partner · 31 March 2026Centessa Pharmaceuticals entered into definitive agreement to be acquired by Eli Lilly. Nxera jointly discovered OX2R agonist pipeline (cleminorexton/ORX750, ORX142, ORX489) using Nxera's NxStaR technology. Nxera retains entitlement to milestone payments and royalties from all OX2R agonists unaffected by acquisition. Nxera holds equity interest in Centessa. Early milestone of US$3 million achieved for ORX489 in March 2026.
  • Santhera PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 8 January 2026Santhera granted Nxera exclusive licensing agreement for development, manufacturing, and commercialization of Agamree (vamorolone) for Duchenne muscular dystrophy in Japan, South Korea, Australia, and New Zealand. Nxera paying US$40 million upfront (US$30 million cash + US$10 million equity investment) with additional potential milestones up to US$165 million plus double-digit tiered royalties on net sales.
  • ShionogicoreChannel Partner/ Reseller/ Distributor · 31 October 2025Partnership with Shionogi for product distribution in Japan supporting QUVIVIQ (daridorexant) demand in Japan and across Asia-Pacific region. Manufacturing approval received for second API manufacturing site in Asia to reduce costs and improve profitability from 2027.
  • Cancer Research UKcoreStrategic or Co-development Partner · 21 October 2025Partnership for cancer immunotherapy drug HTL0039732 (EP4 antagonist). Phase 1 trial successfully completed demonstrating safety and tolerability with early efficacy. Phase 2 expansion trial underway in Japan and UK sponsored by Cancer Research UK. Partial responses observed in patients with resistant tumors including metastatic renal cell and colorectal cancers.
  • AbbVieflagshipStrategic or Co-development Partner · 1 January 2022Multi-target discovery collaboration targeting neurological diseases. Nxera achieved fourth R&D milestone in June 2026 (US$10 million payment), bringing total received to US$40 million since 2022. Nxera remains eligible for up to US$1.2 billion in additional potential option, development and commercial milestones, plus tiered royalties on global sales. Collaboration uses NxWave™ GPCR structure-based drug discovery platform.
  • Eli LillyflagshipStrategic or Co-development Partner · 1 January 2022Multi-target collaboration targeting diabetes and metabolic diseases. Second development milestone achieved in April 2026, validating Nxera's NxWave™ GPCR platform by identifying small molecule binders and solving receptor structures. Nxera eligible for up to US$694 million in development and commercial milestones plus tiered royalties on global sales. Lilly assumes responsibility for further development and commercialization.

Scale indicators16 records

Recent moves9 records

Expansion highlights6 records

Nxera Pharma competitors and assessment

Company assessment

Direct peers

  • Schrödinger, Inc. US-listed (SDGR) computational/structure-based drug design platform company with a software-plus-collaborative-discovery model. Highly comparable to Nxera's NxWave™ platform in combining physics-based modeling, ML, and a wet-lab pipeline to generate partnered and proprietary therapeutic candidates.

Broad incumbents

  • Otsuka Holdings: Diversified Japanese pharma group with significant CNS/psychiatry and specialty disease franchises including schizophrenia. Comparable in CNS therapeutic-area focus and in the Japanese listed-pharma landscape, providing a reference for partner-of-choice economics in Japanese CNS.
  • Idorsia Pharmaceuticals: Swiss-listed specialty CNS biopharma whose operations were integrated into Nxera in 2026. Closely comparable in therapeutic focus (neurology, sleep, rare diseases) and brings daridorexant/QUVIVIQ history to the Nxera platform; a useful reference for what Nxera's CNS specialty pharma footprint could scale to.
  • Karuna Therapeutics (acquired by Bristol Myers Squibb): CNS-focused biopharma (now part of BMS) that developed muscarinic M1/M4 agonism for schizophrenia. Direct comparability to Nxera's muscarinic program (NBI-1117570 with Neurocrine) and schizophrenia franchise including GPR52.
  • Eisai Co., Ltd. Large Japanese pharmaceutical company with significant CNS, neurology, and rare-disease franchises. Comparable in scale and therapeutic-area overlap to Nxera's Japanese CNS commercial footprint and serves as a reference for what a profitable Japan-listed CNS biopharma looks like at scale.
  • Cerevel Therapeutics (acquired by AbbVie): CNS-focused biopharma (now part of AbbVie) with development programs across schizophrenia, Parkinson's, and epilepsy. Comparable in CNS therapeutic focus and a relevant comparable for the value a partnered CNS asset can capture under AbbVie's umbrella — Nxera's own AbbVie partnership uses the same major pharma.

Regional players

  • Shionogi & Co., Ltd. Major Japanese pharmaceutical company and Nxera's distribution partner for QUVIVIQ in Japan/APAC. A relevant Japanese peer given overlapping CNS/anti-infective portfolio and Shionogi's role in commercializing Nxera's CNS products in the home market.

Emerging players

  • OMass Therapeutics: UK-based GPCR-focused drug discovery company using native mass spectrometry and structural biology. Direct comparability in GPCR-focused discovery and the named defendant in Nxera's miniG patent infringement action, making it a particularly informative peer on technology overlap and IP risk.
  • Exscientia plc: AI-centric drug discovery company (EXAI) that has signed multi-target discovery deals with major pharma. Similar to Nxera in the partnered-collaborative revenue model and tech-driven pipeline generation, though Exscientia uses AI/automation rather than GPCR structural biology.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform (RXRX) combining high-throughput biology with ML. Comparable to Nxera in the technology-powered biopharma category, though Recursion's data-generation and target-discovery emphasis is distinct from Nxera's GPCR-structure specialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Nxera Pharma social profiles

Digital presence

Nxera Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nxera Pharma leadership team

Management profile

Number of profiles

Profiles13 records

Nxera Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Nxera Pharma funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nxera Pharma M&A and investment

M&A and investment

M&A3 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nxera Pharma

What does Nxera Pharma do?

Nxera Pharma is a technology-driven biopharmaceutical company that discovers, develops, and commercializes medicines targeting G protein-coupled receptors (GPCRs). Its proprietary NxWave™ platform supports structure-based drug design, and the company markets two products in Japan — PIVLAZ (clazosentan) for cerebral vasospasm prevention and QUVIVIQ (daridorexant) for insomnia — while also generating revenue through licensing deals, milestone payments, and royalties from global pharmaceutical partners.

Is Nxera Pharma a public or private company?

Nxera Pharma is a public company. It is classified as public and is currently operating.

When was Nxera Pharma founded?

Nxera Pharma was founded in 1990. It employs 251 to 500 people.

Where is Nxera Pharma based?

Nxera Pharma is headquartered in Tokyo, Japan, in the Asia region.

How does Nxera Pharma make money?

Five revenue lines are on record. Product Sales are the primary driver. The others are milestone Payments, development and Commercial Milestones, tiered Royalties and licensing Revenue.

Who are Nxera Pharma's main competitors?

Schrödinger, Inc. is listed as a direct peer. Broad incumbents are Otsuka Holdings, Idorsia Pharmaceuticals, Karuna Therapeutics (acquired by Bristol Myers Squibb), Eisai Co., Ltd. and Cerevel Therapeutics (acquired by AbbVie). Shionogi & Co., Ltd. is listed as a regional player. Emerging players are OMass Therapeutics, Exscientia plc and Recursion Pharmaceuticals.

Does Nxera Pharma have an API?

No public API is recorded for Nxera Pharma.

What industry is Nxera Pharma in?

Nxera Pharma's product category is Biopharmaceuticals (GPCR-targeted drug discovery and development). Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AD HOC NEWSAbbVie-Aktie: Executive Vice President verkauft AktienAbbVie executive vice president Jeffrey Stewart sold 40,619 shares on November 9, 2026, valued at $11.93 million. The company also expanded its inflammatory bowel disease pipeline with a licensing deal for NXE0033744 from Nxera. The stock closed at €267.65 on November 14, 2026.TradingViewNxera Pharma Targets South Korea Launch in 2027, One Year EarlierNxera Pharma targets a South Korean launch of vamorolone in 2027, one year earlier than previously announced. The drug was selected for the country's accelerated reimbursement pilot, which aims to shorten National Health Insurance listing to within 100 days. Regulatory approval is targeted for Q3 2027, with timing contingent on review and reimbursement progress.The Pharma LetterNxera Pharma further expands license agreement with AbbVieNxera Pharma entered an exclusive global license agreement with AbbVie for its EP4 agonist NXE0033744, granting AbbVie worldwide rights to develop and commercialize the drug in inflammatory bowel disease. The deal builds on prior collaborations between the two companies.Pharmaceutical TechnologyAbbVie bolsters UK R&D presence, inks $1.38bn IBD deal with Nxera - Pharmaceutical TechnologyAbbVie is expanding its Oxford R&D facility and signed a deal with Nxera for its IBD drug NXE0033744, paying up to $1.37bn in milestones. The UK R&D investment is part of a £120m commitment to the UK life sciences ecosystem.FierceBiotechAbbVie pens $1.4B deal for deprioritized IBD drug from NxeraAbbVie paid $100 million upfront for worldwide rights to Nxera's oral EP4 agonist NXE0033744 for IBD, with up to $1.37 billion in milestones and tiered royalties. The drug, developed with NxWave, passed phase 1 showing gut-restricted activity. Nxera previously deprioritized the program due to competition.YahooNxera Pharma (TSE:4565) Q2 Earnings Put Margin Credibility In FocusNxera Pharma reported Q2 2026 revenue of ¥7,654m, down 9.4% year-over-year, with a net loss of ¥202m, narrowing from ¥2,377m. The company's nine-month core operating profit of ¥9.8b relies on ¥11.8b in milestone receipts and ¥13.3b in partner revenue, raising concerns about margin fragility.Seeking AlphaNxera Pharma Co., Ltd. (SOLTF) Q3 2026 Earnings Call TranscriptNxera Pharma held its Q3 FY2026 earnings call on October 30, 2026, with CEO Chris Cargill and CFO Hironoshin Nomura leading the briefing. The call covered operational highlights, financial results, and Japan APAC commerce updates, with Q&A following.Business & FinancialNxera Pharma Operational Highlights And Consolidated Results For The Third Quarter 2026Nxera Pharma reported Q3 FY2026 revenue of JPY 27,742 million (US$175 million), up JPY 5,894 million from the prior period, driven by ten R&D milestones. The company also advanced partnered programs, including a US$10 million milestone from Neurocrine and a US$8.6 million milestone from Centessa, and submitted a South Korea MAA for vamorolone.GlobeNewswireNxera Pharma Operational Highlights and Consolidated Results for the Third Quarter 2026Nxera Pharma reported Q3 2026 revenue of JPY 27,742 million (US$175 million), up JPY 5,894 million from the prior period, driven by ten R&D milestones. The company also advanced partnered programs, including a US$10 million milestone from Neurocrine and a US$8.6 million milestone from Centessa, and submitted a South Korea MAA for vamorolone.Business & FinancialNxera Pharma Secures Exclusive Rights To Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat For Japan And Selected Asia Pacific MarketsNxera Pharma exercised its option to license lucerastat from Idorsia for Japan, South Korea, Taiwan, and selected Asia Pacific markets, paying CHF 7 million upfront. The oral therapy for Fabry disease has over 400 patient-years of experience, and Idorsia initiated a Phase 3 study FAB-KLEAR. Nxera will manage clinical development in Japan, with a regulatory filing expected as early as 2029.